Kenya PPB Pharmaceutical Import: A 2026 Hospital Sourcing Guide

Kenya is the largest pharmaceutical market in East Africa and the natural regional hub for medicine distribution across the wider region, with Nairobi serving onward markets in Uganda, Tanzania, Rwanda and the Democratic Republic of Congo. For hospital procurement teams, Ministry of Health buyers, NGOs and licensed distributors, the appeal of UK-licensed supply is straightforward: a medicine authorised by the MHRA arrives with a quality and documentation trail that maps cleanly onto what the Kenyan regulator expects to see.

All of that supply is mediated through one institution: the Pharmacy and Poisons Board. Understanding how the PPB works, what documents it requires, how the consignment import permit fits alongside product registration, and where the special import route applies, is the difference between a shipment that clears smoothly and one that sits in quarantine while paperwork is reconciled.

This guide is written for the Kenyan buyer sourcing UK-licensed medicines, and for the UK exporter and local agent supporting them. It covers the regulator, the registration and import-permit pathway, the documentation pack, cold chain expectations, the named patient and special import route, common pitfalls, and how Euro Biom operates the UK export leg of a compliant supply chain.

The PPB: Kenya's Medicines Regulator

The Pharmacy and Poisons Board is the national medicines regulatory authority for Kenya, established under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya. Its remit covers the regulation of the practice of pharmacy and the manufacture of and trade in drugs and poisons. In practice, for anyone importing finished medicines, the PPB does several things that matter directly:

• Product registration. No medicine may be legally sold in Kenya until the product has been registered with the PPB. Registration assesses quality, safety and efficacy and is the gateway to routine commercial supply.
• Import permits. The PPB issues an import permit for each consignment of pharmaceutical products entering the country. This is separate from, and additional to, product registration.
• Premises and professional licensing. Importers, wholesalers, distributors and pharmacies must be licensed, and the technical staff overseeing them must be registered with the Board.
• Inspection and pharmacovigilance. The PPB inspects supply chains, runs post-market surveillance, and operates an electronic pharmacovigilance reporting system for adverse events and quality complaints.

Most regulatory submissions are now handled through the PPB online portal, while the customs-facing import declaration is processed through the Kenya National Electronic Single Window System operated by KenTrade alongside the Kenya Revenue Authority. The two systems work in tandem: the PPB authorises the medicine, and the single window clears the consignment.

For a country-level overview of how Euro Biom serves this market, see our UK pharmaceutical supplier to Kenya page.

Why a Local Agent Is Mandatory

A point that catches many UK suppliers and overseas manufacturers by surprise is that a foreign company cannot register a medicine directly with the PPB. A locally established Kenyan entity must act as the local technical representative, appointed through a Power of Attorney issued by the manufacturer or marketing authorisation holder.

The local agent is not an administrative formality. It is the legal interface with the regulator, and it carries real responsibilities:

• Submitting the product registration dossier through the PPB portal
• Managing the annual retention that keeps a registered product on the register
• Filing variations when a strength, pack size or manufacturing detail changes
• Applying for the consignment import permit for each shipment
• Holding the appropriate import or distribution licence and qualified technical staff
• Acting as the regulatory point of contact, including for pharmacovigilance

For UK-licensed supply, Euro Biom works alongside the Kenyan importer or local agent rather than replacing them. We operate the UK export leg; the local partner manages the in-country PPB interface. The agent's hospital relationships, distribution reach and standing with the Board all materially affect how quickly a product moves from dossier to shelf.

The Registration Pathway, Step by Step

Full product registration is the route for any medicine that will be supplied routinely and at scale in Kenya. The general pathway, for a UK-licensed finished product, looks like this:

1. Appoint the local agent

The manufacturer issues a Power of Attorney to a Kenyan local technical representative who holds the appropriate PPB licence. Nothing else can begin until this is in place.

2. Compile the dossier

The product dossier is assembled in Common Technical Document format, drawing on the UK marketing authorisation. This is where the UK quality documentation does the heavy lifting, because an MHRA-authorised product already carries the quality, safety and efficacy evidence the PPB wants to see.

3. Submit and pay fees

The local agent submits through the PPB portal, with the application formally received only once the application fees are paid. Samples of the product are typically provided for laboratory assessment.

4. Screening, review and queries

The PPB screens the dossier for completeness, then conducts scientific and quality review. Where gaps are found, the Board issues queries that the local agent must answer within the response window. Each query cycle adds time, so a complete first submission is the single most valuable investment in the timeline.

5. Approval and retention

On approval, the product is entered on the register, generally for five years. An annual retention process keeps it there. Once registered, the product is eligible for routine import and for inclusion in tenders run by public buyers such as the Kenya Medical Supplies Authority.

Documents the PPB Typically Requires

The exact list varies by product category and is set by current PPB guidelines, but for a UK-licensed finished medicine the core pack is well established. Use the checklist below as a starting framework, and confirm the live requirements with your local agent before filing.

The Certificate of Pharmaceutical Product is the document most often underestimated. The PPB requires an authentic CPP in WHO format, issued by the originating regulatory authority, which for UK supply means the MHRA Export Certificate service. CPP turnaround from the MHRA typically runs to several weeks, so the request should be built into the project plan early rather than left until a submission deadline is fixed. Where documents are issued in the UK for use in Kenya, legalisation or apostille of certain certificates may also be required, and this should be confirmed with the local agent so it does not become a last-minute bottleneck.

For a fuller treatment of the UK-side export documentation that underpins all of this, see our UK pharmaceutical import documentation guide.

The Consignment Import Permit

Registration gets a product onto the Kenyan market in principle. The import permit gets each actual shipment across the border. The local agent applies for the permit through the PPB portal, and the consignment is then declared through the single window system, where it is matched against the import permit and the IDF before customs release.

A consignment import pack for a registered UK-licensed product generally includes:

• The PPB import permit for the consignment
• A certificate of analysis for the specific batch shipped
• Commercial invoice and packing list
• Bill of lading or air waybill
• The Import Declaration Form processed through KenTrade
• Cold chain temperature records where the product is temperature-sensitive

Because the import permit is consignment-specific, repeat supply into Kenya becomes a rhythm rather than a one-off project. Once a product is registered and the local agent has the import workflow established, subsequent shipments move predictably, which is exactly the kind of reliability hospital procurement teams and Ministry of Health buyers need.

The Named Patient and Special Import Route

Not every clinically needed medicine is registered in Kenya. Specialty oncology agents, rare disease therapies, and certain specialist hospital products often have no registered equivalent in the country. For these cases, the PPB operates a special import route.

Where a Kenyan hospital or Ministry of Health facility can demonstrate a genuine clinical need for a product that is not registered locally, the Board can grant a waiver authorising the import of that unregistered medicine for a defined patient or cohort. It is important to be precise about what this means. The waiver is the buyer's in-country regulatory mechanism, applied for by the prescribing institution or its local agent. The medicine itself remains a UK-licensed, MHRA-authorised finished product that travels with full UK documentation. The route is about the destination country's permission to import an unregistered-in-Kenya product, not about supplying a product that lacks a licence.

This distinction matters for any buyer comparing suppliers. Euro Biom supplies UK-licensed finished medicines only. When a Kenyan hospital sources one of those products through the special import route, it is using its own regulatory pathway to bring in a fully licensed UK medicine that simply has not yet been registered on the Kenyan register. The named patient mechanism is the import route, and the product is a UK-authorised medicine throughout.

This route is the practical answer for:

• Specialty and oncology medicines with no Kenyan-registered equivalent
• Rare disease therapies needed for individual patients
• Acute shortages where a registered product is temporarily unavailable and a clinical gap must be filled quickly

For the UK-side mechanics of how this is handled, see our named patient supply service, and for the broader regional picture, our guide to medicine procurement for African hospitals.

Cold Chain and GDP into Nairobi

A significant share of high-value UK supply into Kenya is temperature-sensitive, including specialty hospital medicines that must be held within a defined range from manufacture to administration. The PPB and the Kenyan port health authorities expect evidence that Good Distribution Practice was maintained across the entire journey.

The core cold chain expectations are:

• Validated storage at origin. The UK exporter holds the product in MHRA-aligned, temperature-controlled facilities at the specified storage temperature.
• Qualified shipping containers. Validated active or passive containers, qualified for the ambient profile of the Heathrow to Nairobi route.
• Continuous monitoring. A calibrated temperature data logger accompanies the consignment from origin packing to delivery, and the record is available for inspection on arrival.
• Stability data covering transit. The manufacturer's stability dossier supports the conditions experienced in transit.
• Documented deviation handling. A procedure agreed with the consignee in advance governs how any temperature excursion is reviewed and either accepted or rejected.

Heathrow to Nairobi is served by direct flights with a flight time of roughly eight to nine hours, which makes tightly controlled cold chain transit and rapid emergency despatch genuinely achievable. For the underlying logistics detail, see our pharma cold chain logistics guide.

Common Pitfalls to Avoid

The same handful of issues account for most delays and rejections. Each is straightforward to prevent.

1. CPP problems

An internal export certificate that is not in WHO format, or a CPP that is out of date, will not be accepted. Request the WHO-format CPP from the MHRA early and check the validity window against your planned filing date.

2. Treating registration and import as one gate

Registration does not remove the need for a consignment import permit, and a waiver-based import does not amount to registration. Map both gates from the outset.

3. Weak local agent selection

The agent's licence status, technical staff, hospital relationships and responsiveness directly affect outcomes. Selecting on retainer cost alone is a frequent and expensive error.

4. Incomplete first submission

Every query cycle adds time. A dossier readiness review with the local agent before filing typically reduces the number of deficiency rounds.

5. Missing legalisation

Some certificates issued in the UK need legalisation or apostille for use in Kenya. Confirm what is required before despatch so it does not stall a consignment at the border.

6. Cold chain excursion handling

Without a pre-agreed deviation procedure, a single excursion can quarantine a consignment for weeks. Embed the procedure in the supply agreement.

How Euro Biom Supports Supply into Kenya

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We supply UK-licensed, MHRA-authorised finished medicines to Kenyan hospitals, Ministry of Health buyers, NGOs and licensed distributors. We are not a manufacturer, a pharmacy or a regulatory consultancy. What we do is operate the UK export leg of a compliant supply chain, working alongside the Kenyan local agent who manages the PPB interface.

Across the Kenyan pathway, our role typically covers:

• UK-side documentation. Coordinating MHRA Certificate of Pharmaceutical Product and free sale certificate procurement with the manufacturer or MA holder, GMP certificate retrieval, and the GDP export pack including CoA, batch release, packing list and commercial invoice.
• Cold chain logistics from Heathrow. GDP-validated temperature-controlled storage, qualified shipping containers, calibrated data loggers, and direct routing into Jomo Kenyatta International Airport, Nairobi.
• Named patient and special import supply. Supplying UK-licensed products that a Kenyan hospital is importing under a PPB waiver, delivered with full UK documentation.
• Shortage supply. Rapid response where Heathrow proximity, MHRA-licensed inventory, and same-day despatch capability are decisive.

To see how Kenya sits within the wider regulatory map, our regulator comparison tool sets the PPB alongside other African and GCC authorities. Our overall capability is summarised on the services page.